CA3026770C - Andrographolide treats progressive forms of multiple sclerosis - Google Patents

Andrographolide treats progressive forms of multiple sclerosis Download PDF

Info

Publication number
CA3026770C
CA3026770C CA3026770A CA3026770A CA3026770C CA 3026770 C CA3026770 C CA 3026770C CA 3026770 A CA3026770 A CA 3026770A CA 3026770 A CA3026770 A CA 3026770A CA 3026770 C CA3026770 C CA 3026770C
Authority
CA
Canada
Prior art keywords
group
multiple sclerosis
progressive
andrographolide
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3026770A
Other languages
English (en)
French (fr)
Other versions
CA3026770A1 (en
Inventor
Juan O. Hancke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNOBIOSCIENCE LLC
Original Assignee
INNOBIOSCIENCE LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INNOBIOSCIENCE LLC filed Critical INNOBIOSCIENCE LLC
Publication of CA3026770A1 publication Critical patent/CA3026770A1/en
Application granted granted Critical
Publication of CA3026770C publication Critical patent/CA3026770C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3026770A 2016-06-08 2017-06-08 Andrographolide treats progressive forms of multiple sclerosis Active CA3026770C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347218P 2016-06-08 2016-06-08
US62/347,218 2016-06-08
PCT/US2017/036463 WO2017214346A1 (en) 2016-06-08 2017-06-08 Andrographolide treats progressive forms of multiple sclerosis

Publications (2)

Publication Number Publication Date
CA3026770A1 CA3026770A1 (en) 2017-12-14
CA3026770C true CA3026770C (en) 2024-05-28

Family

ID=60578163

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026770A Active CA3026770C (en) 2016-06-08 2017-06-08 Andrographolide treats progressive forms of multiple sclerosis

Country Status (8)

Country Link
US (1) US10722492B2 (enExample)
EP (1) EP3468553B1 (enExample)
JP (2) JP6928963B2 (enExample)
CN (1) CN109562097B (enExample)
CA (1) CA3026770C (enExample)
DK (1) DK3468553T3 (enExample)
MX (1) MX386393B (enExample)
WO (1) WO2017214346A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126759A1 (en) * 2017-12-22 2019-06-27 Convelo Therapeutics, Inc. Compounds and methods of promoting myelination
CN109293607A (zh) * 2018-11-14 2019-02-01 株洲千金药业股份有限公司 一种具有抗炎作用的化合物及其在制备抗炎药物中的应用
CN109223770A (zh) * 2018-11-14 2019-01-18 株洲千金药业股份有限公司 一种具有镇痛作用的化合物及其在制备镇痛药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059387A2 (en) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
AU2004315105A1 (en) * 2004-02-03 2005-08-18 Universidad Austral De Chile Composition of labdane diterpenes extracted from Andrographis paniculata, useful for the treatment of autoimmune diseases, and Alzheimer disease by activation of PPR-gamma receptors
AU2012359081B2 (en) * 2011-12-21 2015-09-17 Innobioscience, Llc Combination therapy with interferon and andrographolides for multiple sclerosis

Also Published As

Publication number Publication date
WO2017214346A1 (en) 2017-12-14
JP2019517550A (ja) 2019-06-24
US10722492B2 (en) 2020-07-28
US20190083458A1 (en) 2019-03-21
JP2021165304A (ja) 2021-10-14
DK3468553T3 (da) 2023-07-03
JP6928963B2 (ja) 2021-09-01
MX2018015208A (es) 2019-09-19
CN109562097A (zh) 2019-04-02
EP3468553A4 (en) 2020-02-12
EP3468553A1 (en) 2019-04-17
MX386393B (es) 2025-03-18
CN109562097B (zh) 2022-06-07
CA3026770A1 (en) 2017-12-14
EP3468553B1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
AU2023251426B2 (en) Combinations of cannabinoids and N-acylethanolamines
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US12318380B2 (en) Treatment of demyelinating diseases
JP2021165304A (ja) アンドログラホリドが進化型の多発性硬化症を処置する
CN110300581A (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
WO2018113027A1 (zh) 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
CN115052595B (zh) 用于治疗神经学疾病或病症的新型治疗方法
EP4431093A1 (en) Application of composition containing edaravone and dexborneol in improving or treating cognitive impairment
JP5936707B2 (ja) インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法
WO2022052016A1 (en) Pharmaceutical compositions and uses thereof in treating parkinson's disease
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
HK40115727A (en) Application of composition containing edaravone and dexborneol in improving or treating cognitive impairment
CN120983423A (zh) 狭叶依瓦菊素在制备预防和/或治疗神经炎症的药物中的用途
CN115212194A (zh) 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
HK40021759B (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
HK40018453B (en) Agent for preventing or treating spinocerebellar ataxia
NZ625051B2 (en) Combination therapy with interferon and andrographolides for multiple sclerosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220411

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250416

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250416

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260205